1. Inicio
  2. Publicaciones
  3. Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry

Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Huemer, M
  • Diodato, D
  • Martinelli, D
  • Olivieri, G
  • Blom, H
  • Gleich, F
  • Kolker, S
  • Kozich, V
  • Morris, AA
  • Seifert, B
  • Froese, DS
  • Baumgartner, MR
  • Dionisi-Vici, C
  • Martin, CA
  • Baethmann, M
  • Ballhausen, D
  • Blasco-Alonso, J
  • Boy, N
  • Bueno, M
  • Pelaez, RB
  • Cerone, R
  • Chabrol, B
  • Chapman, KA
  • Couce, ML
  • Crushell, E
  • Diogo, L
  • Ficicioglu, C
  • Jimenez, MCG
  • Silva, MTG
  • Gaspar, AM
  • Gautschi, M
  • Gonzalez-Lamuno, D
  • Gouveia, S
  • Grunewald, S
  • Hendriksz, C
  • Janssen, MCH
  • Jesina, P
  • Koch, J
  • Konstantopoulou, V
  • Lavigne, C
  • Lund, AM
  • Martins, EG
  • Olivas, SM
  • Mention, K
  • Mochel, F
  • Mundy, H
  • Murphy, E
  • Paquay, S
  • Pedron-Giner, C
  • Gomez, MAR
  • Santra, S
  • Schiff, M
  • Schwartz, IV
  • Scholl-Burgi, S
  • Servais, A
  • Skouma, A
  • Tran, C
  • Pinera, IV
  • Walter, J
  • Weisfeld-Adams, J
  • EHOD Consortium

Grupos

Abstract

AimTo explore the clinical presentation, course, treatment and impact of early treatment in patients with remethylation disorders from the European Network and Registry for Homocystinurias and Methylation Defects (E-HOD) international web-based registry. ResultsThis review comprises 238 patients (cobalamin C defect n =161; methylenetetrahydrofolate reductase deficiency n =50; cobalamin G defect n =11; cobalamin E defect n =10; cobalamin D defect n = 5; and cobalamin J defect n = 1) from 47 centres for whom the E-HOD registry includes, as a minimum, data on medical history and enrolment visit. The duration of observation was 127 patient years. In 181 clinically diagnosed patients, the median age at presentation was 30days (range 1 day to 42years) and the median age at diagnosis was 3.7 months (range 3 days to 56years). Seventy-five percent of pre-clinically diagnosed patients with cobalamin C disease became symptomatic within the first 15days of life. Total homocysteine (tHcy), amino acids and urinary methylmalonic acid (MMA) were the most frequently assessed disease markers; confirmatory diagnostics were mainly molecular genetic studies. Remethylation disorders are multisystem diseases dominated by neurological and eye disease and failure to thrive. In this cohort, mortality, thromboembolic, psychiatric and renal disease were rarer than reported elsewhere. Early treatment correlates with lower overall morbidity but is less effective in preventing eye disease and cognitive impairment. The wide variation in treatment hampers the evaluation of particular therapeutic modalities. ConclusionTreatment improves the clinical course of remethylation disorders and reduces morbidity, especially if started early, but neurocognitive and eye symptoms are less responsive. Current treatment is highly variable. This study has the inevitable limitations of a retrospective, registry-based design.

Datos de la publicación

ISSN/ISSNe:
0141-8955, 1573-2665

JOURNAL OF INHERITED METABOLIC DISEASE  WILEY

Tipo:
Article
Páginas:
333-352
PubMed:
30773687
Factor de Impacto:
1,328 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 58

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Compartir